Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults

Vaccination with the 13-valent pneumococcal conjugate vaccine (PCV13) followed ≥ 1 year by the 23-valent pneumococcal polysaccharide vaccine (PPSV23) is recommended for immunocompetent adults ≥ 65 years of age in the United States. This study assessed antipneumococcal opsonophagocytic activity (OPA)...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmoele-Thoma, Beate, van Cleeff, Martin, Greenberg, Richard N., Gurtman, Alejandra, Jones, Thomas R., Sundaraiyer, Vani, Gruber, William C., Scott, Daniel A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6605716/
https://www.ncbi.nlm.nih.gov/pubmed/30648932
http://dx.doi.org/10.1080/21645515.2018.1538618

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6605716/
https://www.ncbi.nlm.nih.gov/pubmed/30648932
http://dx.doi.org/10.1080/21645515.2018.1538618

Ejemplares similares